June 19, 2008 -Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY -) and Kyowa Hakko Kogyo Co., Ltd. (TSE: 4151 - ) today announced that they have formed an exclusive alliance to develop and commercialize ALN-RSV01, an RNAi therapeutic in Phase II clinical devel
opment by Alnylam for the treatment of respiratory syncytial virus (RSV) infection, in Japan and other major markets in Asia... Alnylam's Press Release -
Kyowa Hakko Kogyo's Press Release -
